Pharmacogenomics in the Treatment of Autoimmune Diseases explores genetic factors influencing responses to immunomodulatory therapies. It covers genetic markers that predict efficacy and adverse effects of treatments for conditions like multiple sclerosis, rheumatoid arthritis, and lupus. The book emphasizes personalized approaches to enhance therapeutic outcomes and reduce side effects in autoimmune disease management. Suitable for immunologists and pharmacogenomic specialists, it advances tailored immunotherapies.
Anthony Gordon applies pharmacogenomics to treat autoimmune-related skin conditions such as lupus and dermatomyositis, personalizing immunomodulatory therapies based on genetic profiles. His research explores how genetic variations affect responses to immunosuppressants used in managing autoimmune dermatological disorders. Anthony has published extensively on personalizing autoimmune dermatological treatments through pharmacogenomic testing to enhance efficacy and reduce side effects. He also provides guidelines for clinicians to incorporate pharmacogenomic insights into managing autoimmune skin conditions, promoting personalized and effective dermatological care through genetic-informed immunotherapy strategies.